Q1 EPS Estimates for Sage Therapeutics Increased by Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities research analysts at Wedbush upped their Q1 2025 EPS estimates for Sage Therapeutics in a research note issued on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will earn ($1.17) per share for the quarter, up from their prior forecast of ($1.24). Wedbush has a “Neutral” rating and a $6.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($3.52) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($4.15) EPS, FY2026 earnings at ($2.80) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.22) EPS and FY2029 earnings at ($0.90) EPS.

Several other research firms have also commented on SAGE. Bank of America initiated coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 price objective for the company. Piper Sandler dropped their price target on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Canaccord Genuity Group cut their target price on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday, February 12th. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Finally, Scotiabank dropped their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research note on Wednesday, February 12th. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Sage Therapeutics currently has an average rating of “Hold” and an average price target of $8.81.

Sage Therapeutics Trading Up 0.8 %

Shares of NASDAQ SAGE opened at $7.43 on Friday. The stock has a market capitalization of $456.80 million, a PE ratio of -1.13 and a beta of 0.48. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $14.97. The stock has a fifty day simple moving average of $7.47 and a 200-day simple moving average of $6.72.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%.

Hedge Funds Weigh In On Sage Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SAGE. Picton Mahoney Asset Management lifted its stake in shares of Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 3,581 shares during the period. GAMMA Investing LLC lifted its position in shares of Sage Therapeutics by 16,118.0% during the 1st quarter. GAMMA Investing LLC now owns 8,109 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 8,059 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Sage Therapeutics during the 4th quarter worth approximately $49,000. Ieq Capital LLC acquired a new stake in shares of Sage Therapeutics in the 4th quarter worth approximately $57,000. Finally, Merit Financial Group LLC purchased a new position in Sage Therapeutics in the 1st quarter valued at approximately $87,000. 99.22% of the stock is owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.